Rhythm Pharma says Japan regulator approves IMCIVREE for acquired hypothalamic obesity

Reuters2026/08/24 12:02

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Rhythm Pharmaceuticals won Japan MHLW marketing authorization for IMCIVREE (setmelanotide) to treat acquired hypothalamic obesity.
Launch targeted by end-2026, subject to final pricing.
Approval backed by Phase 3 TRANSCEND data showing an 18.8% placebo-adjusted BMI reduction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rhythm Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608240800PRIMZONEFULLFEED9814829) on August 24, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Rhythm Pharma says Japan regulator approves IMCIVREE for acquired hypothalamic obesity

You may also like

Crypto prices